Investor Relations

The research team at Sunhawk Vision Biotech reported that over-expression of corneal microRNA-328 can lead to dry eye disease. In 2024, the Company successfully tested its proprietary eye drops, SHJ002, and completed a Phase 2 clinical trial for treating dry eye disease in adult patients. The results of this trial showed that SHJ002 significantly improved corneal staining and multiple patient-reported symptoms. Furthermore, there were no SHJ002-related adverse effects and SHJ002 was demonstrated to be highly tolerable. These data indicated that SHJ002 may have a potential to be first-in-class and evolutional eye drops for dry eye disease.